![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SP5 |
Gene summary for SP5 |
![]() |
Gene information | Species | Human | Gene symbol | SP5 | Gene ID | 389058 |
Gene name | Sp5 transcription factor | |
Gene Alias | SP5 | |
Cytomap | 2q31.1 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q6BEB4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
389058 | SP5 | HCC1 | Human | Liver | HCC | 9.85e-15 | 2.88e+00 | 0.5336 |
389058 | SP5 | S014 | Human | Liver | HCC | 6.33e-35 | 1.32e+00 | 0.2254 |
389058 | SP5 | S015 | Human | Liver | HCC | 1.35e-46 | 1.82e+00 | 0.2375 |
389058 | SP5 | S016 | Human | Liver | HCC | 1.32e-57 | 1.71e+00 | 0.2243 |
389058 | SP5 | S027 | Human | Liver | HCC | 2.57e-02 | 1.91e-01 | 0.2446 |
389058 | SP5 | S028 | Human | Liver | HCC | 1.64e-05 | 2.28e-01 | 0.2503 |
389058 | SP5 | S029 | Human | Liver | HCC | 2.14e-02 | 1.35e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586220 | Oral cavity | OSCC | positive regulation of proteolysis | 236/7305 | 372/18723 | 6.53e-22 | 1.38e-19 | 236 |
GO:190336220 | Oral cavity | OSCC | regulation of cellular protein catabolic process | 174/7305 | 255/18723 | 2.04e-21 | 3.70e-19 | 174 |
GO:190305020 | Oral cavity | OSCC | regulation of proteolysis involved in cellular protein catabolic process | 152/7305 | 221/18723 | 2.16e-19 | 3.15e-17 | 152 |
GO:006113620 | Oral cavity | OSCC | regulation of proteasomal protein catabolic process | 132/7305 | 187/18723 | 1.57e-18 | 1.81e-16 | 132 |
GO:200005820 | Oral cavity | OSCC | regulation of ubiquitin-dependent protein catabolic process | 118/7305 | 164/18723 | 9.37e-18 | 9.27e-16 | 118 |
GO:003243420 | Oral cavity | OSCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 100/7305 | 134/18723 | 4.72e-17 | 4.04e-15 | 100 |
GO:004573220 | Oral cavity | OSCC | positive regulation of protein catabolic process | 150/7305 | 231/18723 | 1.06e-15 | 7.64e-14 | 150 |
GO:190336420 | Oral cavity | OSCC | positive regulation of cellular protein catabolic process | 106/7305 | 155/18723 | 1.07e-13 | 5.53e-12 | 106 |
GO:190180018 | Oral cavity | OSCC | positive regulation of proteasomal protein catabolic process | 82/7305 | 114/18723 | 9.33e-13 | 4.22e-11 | 82 |
GO:190305217 | Oral cavity | OSCC | positive regulation of proteolysis involved in cellular protein catabolic process | 92/7305 | 133/18723 | 1.60e-12 | 6.90e-11 | 92 |
GO:007099720 | Oral cavity | OSCC | neuron death | 202/7305 | 361/18723 | 3.75e-11 | 1.23e-09 | 202 |
GO:003243619 | Oral cavity | OSCC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 66/7305 | 90/18723 | 3.76e-11 | 1.23e-09 | 66 |
GO:200006020 | Oral cavity | OSCC | positive regulation of ubiquitin-dependent protein catabolic process | 75/7305 | 107/18723 | 6.67e-11 | 2.06e-09 | 75 |
GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:004340917 | Oral cavity | OSCC | negative regulation of MAPK cascade | 105/7305 | 180/18723 | 1.10e-07 | 1.87e-06 | 105 |
GO:005140217 | Oral cavity | OSCC | neuron apoptotic process | 134/7305 | 246/18723 | 5.65e-07 | 8.19e-06 | 134 |
GO:000961210 | Oral cavity | OSCC | response to mechanical stimulus | 115/7305 | 216/18723 | 1.43e-05 | 1.44e-04 | 115 |
GO:00074925 | Oral cavity | OSCC | endoderm development | 47/7305 | 77/18723 | 7.40e-05 | 5.81e-04 | 47 |
GO:00017063 | Oral cavity | OSCC | endoderm formation | 34/7305 | 54/18723 | 3.12e-04 | 1.94e-03 | 34 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SP5 | SNV | Missense_Mutation | c.1057N>A | p.Glu353Lys | p.E353K | Q6BEB4 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SP5 | SNV | Missense_Mutation | c.1015C>T | p.Arg339Cys | p.R339C | Q6BEB4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR | |
SP5 | SNV | Missense_Mutation | rs779921916 | c.910G>A | p.Gly304Ser | p.G304S | Q6BEB4 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-CI-6621-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
SP5 | insertion | Frame_Shift_Ins | novel | c.784_785insC | p.Leu264ProfsTer118 | p.L264Pfs*118 | Q6BEB4 | protein_coding | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SP5 | insertion | Frame_Shift_Ins | novel | c.58_59insC | p.Ser22GlnfsTer20 | p.S22Qfs*20 | Q6BEB4 | protein_coding | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
SP5 | SNV | Missense_Mutation | novel | c.1032N>T | p.Gln344His | p.Q344H | Q6BEB4 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SP5 | SNV | Missense_Mutation | novel | c.1005G>T | p.Lys335Asn | p.K335N | Q6BEB4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SP5 | SNV | Missense_Mutation | c.1081N>C | p.Cys361Arg | p.C361R | Q6BEB4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-8302-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SP5 | SNV | Missense_Mutation | c.1052N>A | p.Thr351Lys | p.T351K | Q6BEB4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-51-4079-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SP5 | SNV | Missense_Mutation | novel | c.257N>G | p.Pro86Arg | p.P86R | Q6BEB4 | protein_coding | tolerated(0.2) | benign(0.033) | TCGA-68-A59J-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |